MAIA Biotechnology(MAIA) - 2024 FY - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a total of 20,581,469 shares of common stock issued and outstanding as of the record date [6] - Approximately 70.93% of outstanding common stock was represented at the meeting, with 14,598,612 shares entitled to vote [22] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the provided content Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the provided content Company Strategy and Development Direction and Industry Competition - The company ratified the appointment of Grant Thornton as independent auditors for the fiscal year ending December 31, 2024, indicating a focus on maintaining strong governance and compliance [19][23] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook in the provided content Other Important Information - The election of directors was successfully conducted, with Christian Luputz, Ramiro Guerrero, and Vlad Vittok elected to serve for a three-year term [23] - The meeting was adjourned without any objections, and stockholders were invited to submit questions via email [24] Q&A Session Summary - There was no formal Q&A session during the meeting, but stockholders were encouraged to submit questions directly via email after the meeting [23]